- Home
- AKBA vs RCS Comparison
AKBA vs RCS Comparison
Compare AKBA & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- RCS
- Stock Information
- Founded
- AKBA 2007
- RCS 1994
- Country
- AKBA United States
- RCS United States
- Employees
- AKBA N/A
- RCS N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- RCS Investment Managers
- Sector
- AKBA Health Care
- RCS Finance
- Exchange
- AKBA Nasdaq
- RCS Nasdaq
- Market Cap
- AKBA 336.2M
- RCS 292.8M
- IPO Year
- AKBA 2014
- RCS N/A
- Fundamental
- Price
- AKBA $1.80
- RCS $6.32
- Analyst Decision
- AKBA Strong Buy
- RCS
- Analyst Count
- AKBA 1
- RCS 0
- Target Price
- AKBA $7.50
- RCS N/A
- AVG Volume (30 Days)
- AKBA 1.8M
- RCS 141.1K
- Earning Date
- AKBA 03-13-2025
- RCS 01-01-0001
- Dividend Yield
- AKBA N/A
- RCS 10.12%
- EPS Growth
- AKBA N/A
- RCS N/A
- EPS
- AKBA N/A
- RCS N/A
- Revenue
- AKBA $169,879,000.00
- RCS N/A
- Revenue This Year
- AKBA N/A
- RCS N/A
- Revenue Next Year
- AKBA $19.31
- RCS N/A
- P/E Ratio
- AKBA N/A
- RCS N/A
- Revenue Growth
- AKBA N/A
- RCS N/A
- 52 Week Low
- AKBA $0.80
- RCS $4.51
- 52 Week High
- AKBA $2.48
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- AKBA 28.80
- RCS 38.92
- Support Level
- AKBA $2.07
- RCS $6.39
- Resistance Level
- AKBA $2.17
- RCS $6.48
- Average True Range (ATR)
- AKBA 0.08
- RCS 0.13
- MACD
- AKBA -0.05
- RCS 0.02
- Stochastic Oscillator
- AKBA 4.60
- RCS 9.38
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.